These studies further indicate that ER and RSL3 are important modulators of ovarian cell death and may provide excellent combinatorial therapy for treating resistant cancers, including those with K-RAS mutations and/or expressing MDR phenotypes. The gene discussed is KRAS; the disease is cancer.